• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by CervoMed Inc.

    2/11/26 1:21:33 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CervoMed Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    15713L109

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    15713L109


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    470,631.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    473,681.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    473,681.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    CUSIP No.
    15713L109


    1Names of Reporting Persons

    Morgan Stanley Capital Services LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    470,631.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    470,631.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    470,631.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    BD, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CervoMed Inc
    (b)Address of issuer's principal executive offices:

    20 PARK PLAZA, SUITE 424, BOSTON, MA, 02116
    Item 2. 
    (a)Name of person filing:

    1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
    (b)Address or principal business office or, if none, residence:

    1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
    (c)Citizenship:

    1: Delaware 2: Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    15713L109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit 99.2
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:02/11/2026
     
    Morgan Stanley Capital Services LLC
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley Capital Services LLC
    Date:02/11/2026
    Exhibit Information

    EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

    Get the next $CRVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    12/18/2025Overweight
    Cantor Fitzgerald
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    More analyst ratings

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Quigley David

    4 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:16:27 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Quigley David

    3 - CervoMed Inc. (0001053691) (Issuer)

    12/5/25 6:15:03 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

    Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Today in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by C

    12/4/25 5:00:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

    1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma GFAP with positive treatment response, as assessed by CDR-SB, support neflamapimod mechanism of action and suggest it may act on underlying disease BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company devel

    12/2/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

    11/10/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gregoire Sylvie bought $182,736 worth of shares (21,600 units at $8.46), increasing direct ownership by 0.73% to 1,484,078 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:56 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO, GC & Secretary Elder William Robert bought $29,250 worth of shares (3,500 units at $8.36), increasing direct ownership by 39% to 12,500 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:45:32 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on CervoMed

    Cantor Fitzgerald initiated coverage of CervoMed with a rating of Overweight

    12/18/25 9:09:07 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

    3/13/25 7:28:49 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CervoMed from Buy to Neutral

    12/17/24 7:40:50 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by CervoMed Inc.

    SCHEDULE 13G - CervoMed Inc. (0001053691) (Subject)

    2/11/26 1:21:33 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    1/8/26 4:08:44 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    12/5/25 4:05:42 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Financials

    Live finance-specific insights

    View All

    CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

    Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

    7/28/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

    Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, July 24, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company will host a conference call and webcast on Monday, July 28 at 8:00 AM ET to share new results, including the primary endpoint results at 32-weeks of the Extension phase, from the Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bod

    7/24/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

    A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

    3/10/25 4:05:00 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    View All

    CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

    Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026 Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia (FTD) and topline results from Phase 2a trial in recovery aft

    11/10/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

    Mr. Quigley most recently led McKinsey & Company's Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm's Life Sciences and Private Eq

    10/28/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

    BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnology industry, leading organizations through scientific breakthroughs, growth and innovation, and market transformation. "It is a pleasure to welcome Matthew, an experienced and proven leader and organization builder," said John Alam, M.D., Chief Executive Officer of CervoMed. "This appointment comes at a pivotal ti

    10/7/25 8:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    11/14/24 3:09:10 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    4/11/24 7:55:23 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

    SC 13G/A - CervoMed Inc. (0001053691) (Subject)

    3/6/24 4:05:55 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care